{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:42:52Z","timestamp":1755218572150,"version":"3.43.0"},"reference-count":29,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>CAR\u2010T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early\u2010line MM raises questions on the acceptability of upfront risks in exchange for extended relapse\u2010free periods without the treatment burden and limitations on daily activities associated with maintenance therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A discrete\u2010choice experiment was designed to elicit adults' preferences for hypothetical NDMM treatments. Benefits included time to relapse and reduction of treatment impact on daily activities. Severe adverse events were included to better understand patient preferences for rare but significant events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>On average, extending the time to relapse from 3\u2009years (with moderate limitations on daily activities) to 5\u2009years (without limitations) was three times more important than avoiding a 20% risk of hospitalization due to severe ICANS\/CRS. Analysis revealed three latent preference classes: a benefit\u2013risk trading class (65%), a class (28%) unwilling to accept increases in short\u2010term treatment\u2010related mortality, and a class (7%) that provided statistically uninformative data. For the trading class, for two additional relapse\u2010free years with minor limitations, all else equal, patients would accept up to a 30% risk of severe ICANS\/CRS\u2010related hospitalization along with 0% risk of treatment\u2010related mortality. Alternatively, they would accept up to an 8% risk of treatment\u2010related mortality with a 0% risk of severe ICANS\/CRS\u2010related hospitalization, or various combinations of lower AE risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results reveal preference heterogeneity among MM patients and the importance of effective communication about the benefits and risks of novel therapies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.71072","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T07:20:01Z","timestamp":1752909601000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying Preferences for <scp>CAR<\/scp>\u2010T Compared to Standard of Care as a First\u2010Line Treatment Among Patients With Multiple Myeloma"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-3677","authenticated-orcid":false,"given":"Jessie","family":"Sutphin","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Janssen","sequence":"additional","affiliation":[{"name":"Janssen Research and Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-1293","authenticated-orcid":false,"given":"Laura","family":"Hester","sequence":"additional","affiliation":[{"name":"Janssen Research and Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Reed","family":"Johnson","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby D.","family":"Reed","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159169"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_2_12_8_1","first-page":"86","article-title":"Cartitude\u20102 Cohort B: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel in Patients With Multiple Myeloma and Early Relapse After Initial Therapy","volume":"6","author":"Agha M. E.","year":"2022","journal-title":"European Hematology Association"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829568.10814.bc"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010018\u20100734\u20102"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","unstructured":"S. Z.Usmani J. G.Berdeja D.Madduri et\u00a0al. \u201cCiltacabtagene Autoleucel a B\u2010Cell Maturation Antigen (BCMA)\u2010Directed Chimeric Antigen Receptor T\u2010Cell (CAR\u2010T) Therapy in Relapsed\/Refractory Multiple Myeloma (R\/R MM): Updated Results From CARTITUDE\u20101 \u201dPresentation 2021 ASCO Annual meeting.","DOI":"10.1016\/j.htct.2021.10.460"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u20100298\u20101"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103744"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159381"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.01.016"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S235430"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010023\u201000671\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X07304449"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15581800"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X221132266"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/23814683221148715"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102021\u20100160"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102022\u20100421"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S345906"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1027353"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u201007018\u20106"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:02:26Z","timestamp":1754460146000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/cam4.71072"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71072","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71072"}}